CN116999390A - Electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and preparation method thereof - Google Patents
Electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and preparation method thereof Download PDFInfo
- Publication number
- CN116999390A CN116999390A CN202310958412.5A CN202310958412A CN116999390A CN 116999390 A CN116999390 A CN 116999390A CN 202310958412 A CN202310958412 A CN 202310958412A CN 116999390 A CN116999390 A CN 116999390A
- Authority
- CN
- China
- Prior art keywords
- silver
- electrolytic
- complexing agent
- ion solution
- silver ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 title claims abstract description 123
- 241000725303 Human immunodeficiency virus Species 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 16
- 229910052709 silver Inorganic materials 0.000 claims abstract description 113
- 239000004332 silver Substances 0.000 claims abstract description 113
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 73
- -1 silver ions Chemical class 0.000 claims abstract description 65
- 239000008139 complexing agent Substances 0.000 claims abstract description 51
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical group C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 16
- 235000010299 hexamethylene tetramine Nutrition 0.000 claims abstract description 12
- 239000004312 hexamethylene tetramine Substances 0.000 claims abstract description 12
- 229910021642 ultra pure water Inorganic materials 0.000 claims abstract description 10
- 239000012498 ultrapure water Substances 0.000 claims abstract description 10
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000002500 ions Chemical class 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 95
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 11
- 230000032683 aging Effects 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 230000005684 electric field Effects 0.000 claims description 4
- 229920006351 engineering plastic Polymers 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 229910000510 noble metal Inorganic materials 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000010668 complexation reaction Methods 0.000 claims description 2
- 238000005868 electrolysis reaction Methods 0.000 claims description 2
- 239000012212 insulator Substances 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002779 inactivation Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 19
- 238000001514 detection method Methods 0.000 description 18
- 241000700605 Viruses Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000002147 killing effect Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000002381 microspectrum Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010058667 Oral toxicity Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 231100000418 oral toxicity Toxicity 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003926 complexometric titration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003239 environmental mutagen Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- RLLVZNQBQJNFBG-UHFFFAOYSA-N hydrogen peroxide;silver Chemical compound [Ag].[Ag].OO RLLVZNQBQJNFBG-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical preparations, and relates to an electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and a preparation method thereof. The electrolytic silver ion solution takes ultrapure water as a solvent, and contains positive divalent silver ions, a complexing agent and a complexing agent; the complexing agent is hexamethylenetetramine which can form a stable complex with silver ions and can quantitatively analyze the concentration of the silver ions; hexamethylenetetramine is of analytically pure grade; the complexing agent can form more stable silver ammine complex ion with silver ion, i.e. diammine silver, and can make the formed silver ammine complexAnalytically pure grade ethylenediamine with a multiple increase in ion concentration; the concentration of the positive divalent silver ions is 200-300 mg.kg ‑1 The method comprises the steps of carrying out a first treatment on the surface of the The maximum concentration of complexing agent is 0.9g.kg ‑1 The method comprises the steps of carrying out a first treatment on the surface of the The highest concentration of complexing agent is 0.55g.kg ‑1 . The complexing agent and the complexing agent have the advantages of small dosage, high relative ratio of silver ions, stronger activity and high inactivation rate of 99.993 percent on HIV.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to an electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and a preparation method thereof.
Background
Acquired immunodeficiency syndrome (Acquired Immune Deficiency Syndrome, AIDS) is simply called AIDS, and is an infectious disease with high mortality. AIDS is caused by infection with human immunodeficiency virus (Human Immunodeficiency Virus, HIV). HIV primarily attacks T cells in the patient, disrupting their cellular immune function, causing them to undergo various serious opportunistic infections.
Since the 90 s of the 20 th century, the use of highly potent antiretroviral therapy for the treatment of aids, also known as "cocktail therapy" i.e. HAART, has been initiated clinically; HAART can effectively inhibit reproduction of AIDS virus and reduce death rate of patients.
However, the treatment of aids by cocktail therapy still cannot completely remove HIV, and because the aids still survive in cells and are not killed, once the drug is stopped, the viruses are again propagated in large quantity, and the aids recur, so that the aids at the present stage is only a chronic disease which can be treated and has efficacy but cannot be cured.
AIDS virus is RNA virus, has higher replication rate and mutation rate, so patients need to take the medicine for life, and the medicine cost is high and the side effect is huge.
That is, the existing anti-AIDS drugs are basically in the category of the pseudo-viral preparation, and cannot kill the HIV hidden in immune cells, so the existing anti-AIDS drugs are "treating the symptoms and not treating the root cause". This is also the biggest defect of current drugs for treating AIDS-!
The innovation of the anti-AIDS medicine is still one of the main fields with larger national gap between China and Europe and America.
As early as 2011 and 2013, lara H and Mori Y et al reported: the nano silver can inhibit various viruses such as HIV, HBV, influenza virus H1N1 and the like, and the antiviral effect of the nano silver is mainly caused by silver ions released by the 111 crystal face and the 100 crystal face of the nano silver.
However, since nano silver is silver particles with the particle size of about 100nm, the nano silver particles can be immediately phagocytized by phagocytes as foreign matters after entering the organism, and the phagocytes are killed by the nano silver at the same time of being phagocytized and cleared, so that the immune system of the organism is rapidly collapsed, and main organs such as lung, liver, kidney and the like of the organism are rapidly infected, exhausted and necrotized, which is a main reason that nano silver products cannot be used for treating AIDS by oral administration and vascular injection so far.
The electrolytic silver ion solution of the invention is a metal pharmaceutical preparation taking silver ions as the center, wherein the valence of the silver ions is high, namely 2, and the electrolytic silver ion solution with high valence is also called as high valence.
Most of silver ion products supplied in the market at present are silver nitrate systems, the valence of silver ions in the systems is monovalent, the silver nitrate solution with low valence is extremely poor in stability, and silver chloride white sediment is easily generated by reaction with chloride ions in physiological saline in blood to plug capillaries at all levels to cause dangerous complications, so that the low-valence silver ion products sold in the market at present cannot enter the body absolutely.
Therefore, research and development of drugs capable of safely entering the body to thoroughly kill the HIV hidden in immune cells is urgent-!
The invention patent ZL202010395234.6 discloses an antibacterial and antiviral high-valence electrolytic silver ion solution and a preparation method thereof, the patent does not report the specific killing effect of the electrolytic silver ion solution on HIV, and the complexing agent for preparing the high-valence electrolytic silver ion solution are too high in dosage, so that the impurity content ratio is large, the silver ion ratio is low, and the curative effect is seriously affected; meanwhile, a large number of ultrasonic oscillators and labyrinth structures are adopted in the preparation method, so that the structure is complex, the energy and the consumption materials are consumed, and noble metal silver particles which are oscillated and shed from the cathode are seriously wasted.
Disclosure of Invention
The invention aims at overcoming the defects of the prior art and provides an electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and a preparation method thereof. The complexing agent and the complexing agent of the electrolytic silver ion solution have the advantages of small dosage, high relative ratio of silver ions, stronger activity and high inactivation rate to HIV (human immunodeficiency Virus) up to 99.993%; the preparation device of the electrolytic silver ion solution has novel and simple structure, no complex ultrasonic oscillator and no labyrinth facility, high automation degree, little power consumption, high utilization rate of metal silver plate material and little waste.
The invention adopts the following technical scheme for accomplishing the purposes:
the electrolytic silver ion solution takes ultrapure water as a solvent, and contains positive divalent silver ions, complexing agent and complexing agent; the complexing agent is hexamethylenetetramine which can form a stable complex with silver ions and can quantitatively analyze the concentration of the silver ions; the hexamethylenetetramine is of an analytically pure grade; the complexing agent is analytically pure grade ethylenediamine which can form more stable silver ammino ion, namely diammine silver, with silver ion, and can increase the concentration of the generated silver ammino ion by times; the concentration of the positive divalent silver ions is 200-300 mg kg -1 The method comprises the steps of carrying out a first treatment on the surface of the The maximum concentration of the complexing agent is 0.9g.kg -1 The method comprises the steps of carrying out a first treatment on the surface of the The highest concentration of the complexing agent is 0.55g.kg -1 The method comprises the steps of carrying out a first treatment on the surface of the The p H value of the electrolytic silver ion solution is 10.2-10.5.
The ultrapure water is water with resistivity of 10-12MΩ cm (25 ℃).
A preparation method of electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus comprises the following specific steps:
1) Injecting ultrapure water into the electrolytic tank, wherein the horizontal plane is 10cm away from the upper end surface of the electrolytic tank; the electrolytic tank is an insulator, silver electrode plates made of high-purity silver plates are respectively placed at two ends of the electrolytic tank, the specifications of the two silver electrode plates are identical, a stirrer is arranged at the center of the electrolytic tank, the silver electrode plates at the two ends of the electrolytic tank are respectively connected with a direct current power supply capable of automatically reversing the positive electrode and the negative electrode, the positive electrode and the negative electrode are not separated, the positive electrode and the negative electrode can be both positive electrode and negative electrode, the periodic transformation is carried out, and the reversing time is controlled between 1 minutes and 15 minutes;
(2) Starting the stirrer, slowly increasing the rotation speed to 800-1500 rpm, and keeping the water temperature at 15-20 ℃ all the time in the subsequent reaction process based on the highest rotation speed when the water surface is stable and does not overflow 0 C；
(3) Adding a complexing agent and a complexing agent into the electrolytic tank, and stirring to fully dissolve the complexing agent and the complexing agent;
(4) After the complexing agent and the complexing agent are fully dissolved, a direct current power supply capable of automatically reversing the positive electrode and the negative electrode is started, so that the positive electrode or the negative electrode of the silver electrode plate at the two ends is automatically converted within a set time, silver atoms on the high-purity silver plate are electrolyzed to obtain monovalent silver ions, the monovalent silver ions obtained by electrolysis enter water under the attraction of an electric field and then are subjected to complexation reaction with the complexing agent and the complexing agent to generate a diammine silver complex taking positive and divalent silver ions as a core, the two electrode plates are positive-negative electrodes and negative-positive electrodes, the time for automatically reversing the positive electrode and the negative electrode is 1-15 minutes, and the positive electrode and the negative electrode are periodically converted, so that the additional loss of noble metal silver materials is avoided except for silver ions generated in water; in the reaction process, detecting the concentration of positive divalent silver ions in the aqueous solution every 1h, when the concentration of the silver ions is 200-300 mg.kg -1 When in use, the automatic positive and negative electrode reverse DC power supply is turned off timely according to the requirement,and (3) aging at a rotating speed of 200 revolutions or less by only maintaining the stirrer, and adjusting the PH value of the electrolytic silver ion solution to be 10.2-10.5 after the aging is performed for 48 hours, thereby obtaining the electrolytic silver ion solution capable of completely inactivating the HIV.
The specification of the direct current power supply capable of automatically reversing the positive electrode and the negative electrode is as follows: the voltage is 10-100V, the current is 0.5-30A, and the time for automatically reversing the positive and negative electrodes is 1-15 minutes.
The preparation material of the electrolytic cell is engineering plastic, and the shape of the electrolytic cell is optimal by taking a cube as a best.
The purity of the high-purity silver plate in the electrode plate is 99.9-99.99%, the thickness is 0.5-4.0 mm, and the area of the electrode plate is 60-80% of the inner surface area of the two ends of the electrolytic cell.
The power of the motor of the stirrer is 1-6 kW, the speed is regulated in a variable frequency mode, the rotating speed range is 60-1800 revolutions, and the blades of the stirrer are engineering plastics.
The electrolytic silver ion solution capable of completely inactivating the HIV and the preparation method thereof provided by the invention have the following outstanding advantages and effects:
in the electrolytic silver ion solution of the invention, the highest concentration of the complexing agent and the complexing agent with non-therapeutic effect is only less than 50 percent of that of the patent ZL202010395234.6, and the concentration of the silver ion with therapeutic effect is increased by times, thereby obviously reducing the side effect of auxiliary materials, increasing the therapeutic effect of the silver ion of main medicine, and the inactivation rate of the inactivated HIV of the electrolytic silver ion solution of the invention reaches 99.993 percent within 1 hour through the detection result of Shanghai micro-spectrum, which is very exciting-!
(2) The complexing agent hexamethylenetetramine used in the electrolytic silver ion solution of the invention not only can be in the form of silver ions
In a stable complex, and can quantitatively analyze the concentration of silver ions, hexamethylenetetramine is a common complexometric titration reagent which realizes the quantitative analysis of metal ions through the complex formed by the hexamethylenetetramine and the metal ions in the to-be-detected object.
The complexing agent ethylenediamine used in the electrolytic silver ion solution disclosed by the invention is not only a common complexing agent, but also has stronger alkalinity than ammonia water, the silver ammino ion formed by ethylenediamine and silver ions is not only stronger in stability than the silver ammino ion formed by ammonia water and silver ions, but also has the concentration 1 time higher than that of the silver ammino ion formed by ammonia water and silver ions, and the repeated detection proves that the complexing agent ethylenediamine is fully used in a light-resistant experiment or a high-temperature-resistant experiment or a silver ion depth measurement, and is consistent with the report of journal of chemical teaching in 1995, so that the stability and the high concentration of the electrolytic silver ion solution are very important, the effective period of the electrolytic silver ion solution is obviously influenced, and the use effect and the improvement of the curative effect are very important.
The electrolytic silver ion solution preparation device disclosed by the invention has the advantages of novel and simple structure, low power consumption, high automation degree, automatic periodic inversion and conversion of positive and negative polarities of the silver plates at the two ends, no need of manual frequent adjustment, no extra consumption of silver plate electrodes, and no waste of metallic silver materials.
The electrolytic silver ion solution has strong inactivation rate to HIV, which is a great finding and is incomparable with general antiviral drugs.
The electrolytic silver ion solution of the invention has no corrosiveness, no irritation, and no drug resistance, and can be taken orally, or can be injected intravenously or inhaled by atomization.
Drawings
FIG. 1 is a schematic view showing the structure of an electrolytic cell for producing an electrolytic silver ion solution of the present invention, wherein: 1. an electrolytic tank 2, an anode silver plate 3, a cathode silver plate 4, a stirrer 5 and a direct current power supply with the positive and negative poles automatically reversed;
FIGS. 2-1, 2-2, 2-3, 2-4 are experimental reports of the Shanghai micro-spectra of killing AIDS virus of the electrolytic silver ion solution of the present invention;
FIG. 3 is a report of the experiment of the electrolytic silver ion solution of the present invention without hemolysis after the electrolytic silver ion solution of the present invention is added to human blood;
fig. 4 is a conclusion of the study of silver ion toxicity in the journal of pharmaceutical research in 2017, professor Sun Jianfei of the Shandong province of medicine: the silver ion concentration is less than 12.5 ppm without cytotoxicity.
FIG. 5 is an oral half-lethal dose of electrolytic silver ion solutionLD 50 Toxicity detection report of (2);
FIGS. 6-1 and 6-2 show half of the death rate LD of intraperitoneal injection of electrolytic silver ion solution 50 Toxicity detection report of (2);
FIG. 7 is a report of pathological section detection of lung, liver and kidney after 10 days of intravenous injection of electrolytic silver ion solution;
FIG. 8 is a report of the detection of the killing of H1N1 viruses by electrolytic silver ion solutions;
description of the embodiments
The present invention is further illustrated by the following examples, which are intended to be illustrative of the invention and not limiting, and simple modifications or numerical substitutions of the invention within the intended spirit of the invention and the scope of the claims are within the scope of the invention.
Examples
Adding 500kg of ultra-pure water into a GY-500 small-sized electrolytic tank, starting a stirrer, rotating at 850 r, slowly adding 0.4kg of complexing agent hexamethylenetetramine under stirring, slowly adding 0.25kg of complexing agent ethylenediamine after 10 minutes, stirring for 10 minutes, starting a direct current power supply with the positive and negative poles automatically reversed, adjusting the voltage to 5-35V, the current to 0.5-3.6A, and controlling the water temperature to 15-20 0 C, sampling and detecting silver ion concentration once per hour until the silver ion concentration in the solution reaches 200mg.kg -1 When the direct current power supply with the anode and the cathode automatically reversing is turned off, only stirring is kept, but the rotating speed of the stirrer is reduced to about 200 revolutions, the low-speed aging is carried out for 1-2 days, namely, the machine is completely stopped, the PH is adjusted to 10.2, the stabilized electrolytic silver ion solution is packaged and packaged in the next day, and the product is stored in a shade place, thus obtaining the formal electrolytic silver ion solution product.
Examples
1000kg of ultra-pure water is added into a GY-1000 medium-sized electrolytic tank, a stirrer is started, the rotating speed is 1100 turns, the complexing agent hexamethylenetetramine is slowly added under stirring for 0.9kg without splashing and overflowing, the complexing agent ethylenediamine is slowly added after 10 minutes, the direct current power supply with the anode and the cathode automatically reversed is started after 10 minutes of stirring, the voltage is regulated to 10-40V, the current is regulated to 0.8-6.8A, and the water temperature is controlled to 15-20 0 C (C)The silver ion concentration is detected by sampling every hour until the silver ion concentration in the solution reaches 250mg.kg -1 When the direct current power supply with the anode and the cathode automatically reversing is turned off, only stirring is kept, but the rotating speed of the stirrer is reduced to about 180 turns, the machine is completely stopped after low-speed aging for 2 days, the PH is adjusted to 10.4, and the stabilized electrolytic silver ion solution is packaged and packaged in the next day and stored in a shade place, so that the formal product of the electrolytic silver ion solution is obtained.
Examples
Adding 2000kg of ultra-pure water into a GY-2000 large-sized electrolytic tank, starting a stirrer, rotating at 1400 revolutions, based on no splashing and no overflow of water flow, slowly adding 1.7kg of complexing agent hexamethylenetetramine under stirring, slowly adding 1.0kg of complexing agent ethylenediamine after 10 minutes, stirring for 15 minutes, starting a direct current power supply with the positive and negative electrodes automatically reversed, adjusting the voltage to 15-50V, the current to 1.7-14.5A, and controlling the water temperature to 15-20 0 C, sampling and detecting silver ion concentration once per hour until the silver ion concentration in the solution reaches 300mg.kg -1 When the direct current power supply with the anode and the cathode automatically reversing is turned off, only stirring is kept, but the rotating speed of the stirrer is reduced to about 280 turns, the machine is completely stopped after low-speed aging for 2 days, the PH is adjusted to 10.3, and the stabilized electrolytic silver ion solution is packaged and packaged in the next day and stored in a shade place, so that the formal product of the electrolytic silver ion solution is obtained.
The mechanism of the electrolytic silver ion solution for killing the HIV is clear and easy to understand: the HIV proteins are negatively charged,
silver ions are positively charged, and the silver ions are mutually attracted and tightly combined, so that the HIV is denatured, coagulated, degraded and dead.
The electrolytic silver ion solution of the invention is detected by Shanghai micro-spectrum detection technology group Co., ltd.12 days in 2023, 06 month, detection number: SHA01-23040893-JC-01, virus detection: HIV-1 strain llB, supplied by Wohawided Bio-medicine Co., ltd; detecting cells: c8166 Tibetan toxic cells were supplied by wuwei li bio-pharmaceutical limited; detection result: the inactivation rate of the electrolytic silver ion solution to HIV-1 is 99.993% under the condition of 1 hour at room temperature, and is shown in the specification of figures 2-1, 2-2, 2-3 and 2-4.
It should be noted that: the electrolytic silver ion solution is absolutely different from common disinfectants such as 75% ethanol and 84 disinfectant, and although the common disinfectants can kill HIV, the common disinfectants can not be taken orally or injected into the body through blood vessels, and can not be sprayed on mucous membranes of eyes and nasal cavities, and the electrolytic silver ion solution (also called high-valence electrolytic silver ion solution) has no corrosiveness, no irritation and no drug resistance, and can be taken orally or injected through blood vessels, injected intraperitoneally, atomized inhaled, sprayed on mucous membranes of eyes and nasal cavities, which are completely proved by practice.
Because the electrolytic silver ion solution has good compatibility with physiological saline, the electrolytic silver ion solution can not be catalyzed by the cell after entering blood like 2-valent calcium and magnesium ions, and can kill the HIV hidden in immune cells along with the entering of saline into the cells.
As shown in FIG. 3, after the electrolytic silver ion solution is added into the blood, the red blood cells are in normal morphology and left for 24 hours
No change and no hemolysis, which indicates that the electrolytic silver ion solution has good compatibility with blood.
The electrolytic silver ion solution has the characteristic of no drug resistance, no matter how the HIV is mutated, the outer shell of the electrolytic silver ion solution is protein, and silver ions can chase the outer protein adhered with the HIV, so that the HIV dies.
The electrolytic silver ion solution of the invention also has broad-spectrum antiviral property: 2020. the electrolytic silver ion solution was tested for antiviral activity at the national institute of microbiology, guangzhou, 27 days, test number: KY20200156, test strain: A/PR8/34H1N1, toxic carrying cells: MDCK cells, detection results: the high-valence electrolytic silver ion solution has a killing rate of 75.45 percent on H1N1 virus within 30 minutes; the H1N1 virus is still representative in virus series, which demonstrates the broad-spectrum antiviral performance of the electrolytic silver ion solution from another angle, and the detection result of Shanghai micro-spectrum also proves the broad-spectrum antiviral performance of the electrolytic silver ion solution, and prompts that the electrolytic silver ion solution has higher killing rate to HIV, see figure 8.
That is, no matter what viruses, silver ions can be killed, and the only difference is that the killing rate is different for different viruses. 5.6 hundred million silver ions are contained in every 1 ml of silver ions at a concentration of 10ppm, and the virus killing capacity is very strong ≡!
The society of medicine, shandong, university, sun Jianfei in 2017 teaches the conclusion of a study on silver ion toxicity reported in the journal of pharmaceutical research: the silver ion concentration is less than 12.5 ppm without cytotoxicity. See fig. 4 for a report picture.
The common concentration of the electrolytic silver ion solution is 2-10 ppm, that is to say, the electrolytic silver ion solution can not only kill HIV with high efficiency but also has no toxicity to organism cells-!
Mechanism of the electrolytic silver ion solution not toxic to normal cells while killing viruses:
the inherent characteristic of the electrolytic silver ion solution is that the electrolytic silver ion solution can be tightly combined with protein, and after entering the organism, silver ions can be combined with viruses and normal cells, that is, the silver ions can damage the normal cells while killing the viruses, but the average diameter of the viruses is 100nm, namely 0.1um, the average diameter of the cells is 15um, the volume is converted into volume, and the volume of the cells is more than 337 ten thousand times of the volume of the viruses-! When the concentration of silver ions is 1-10 ppm, viruses with vast small volumes can be effectively killed, but cells with huge volumes cannot be killed, and only the cells are subjected to transient slight stimulation; this is also consistent with the results of the study taught by Sun Jianfei: the silver ion concentration is less than 12.5 ppm without cytotoxicity.
It can be said that the electrolytic silver ion solution has almost no side effect while killing HIV.
This can be illustrated by practicing the test results as follows: oral toxicity detection (see figure 5), intraperitoneal injection toxicity detection (see figures 6-1 and 6-2) of the electrolytic silver ion solution, liver and kidney function detection after 10 days of intravenous injection of animals and pathological section detection (see figure 7) of lung, liver and kidney all show that the electrolytic silver ion solution has no cytotoxicity to normal cells when the concentration is 1-10 ppm; in fig. 7, reference numerals 1, 2 and 3 denote control groups, and reference numerals 4, 5 and 6 denote experimental groups.
The electrolytic silver ion solution is colorless and transparent, has no irritation, no corrosiveness and no drug resistance, has the appearance similar to mineral water, and can be stored for 2-4 years at room temperature.
The electrolytic silver ion solution can be produced in industrial batch, and the use method is simple and convenient: can be orally taken, can be intravenous drip, can be intramuscular injected, can be injected into abdominal cavity and chest cavity, can be atomized and inhaled, has a parent price, is convenient for large-area popularization and use, and is particularly suitable for the national conditions of China.
Silver and iron are strictly academic heavy metals, but silver and iron are in-vitro metals, are trace elements in human tissues, trace silver is harmless to human bodies, and drinking water with silver ion concentration lower than 0.1ppm does not cause adverse effects on human bodies according to the fourth edition of world health organization drinking water quality guidance standard recently issued by WHO.
Silver is divided into nano silver, colloid silver and silver ions, the nano silver and the colloid silver belong to simple substance silver, accumulation is possible in a body, however, an electrolytic silver ion solution is in an ionic state and has positive charges, and the electrostatic electric field intensity of the positive charges of the electrolytic silver ions is larger than the weight of the electrolytic silver ions, so that the silver ions cannot be precipitated and accumulated.
After Coombs C J used silver sulfadiazine for 6h in 1992 on 22 burn patients, the highest silver ion content in blood can reach 310ug.kg -1 The silver ion discharged from urine of a patient per day is 100-400 ug, and after 15 days, the silver ion can be safely discharged to the outside of the body, so that the silver ion can not be accumulated in the body, the environmental pollution is avoided, and the concentration of the silver ion entering the blood can reach 20mg.kg at the highest when the sulfadiazine silver is used for treating burn wound surfaces -1 。
The medical college Chen in wenzhou reports in 2004 that silver ions entering blood through the silver-loaded auxiliary material layer can be safely discharged to the outside through urine within 14 days and restored to the level before treatment, the silver metabolism in the body belongs to a safe range, and the silver content in the blood of normal people is 1.54+/-1.09 ug -1 The silver content in urine is 1.0+ -0.71 ug.kg -1 UsingAfter 5 days of silver auxiliary material, the silver auxiliary material reaches 3.88+/-4.42 ug/kg respectively -1 And 3.68.+ -. 4.99ug -1 The silver content returns to the level before treatment on the 9 th day of the stop of the silver auxiliary material, and the human body has the functions of automatic metabolism and no accumulation of silver ions in the body.
Silver has an atomic weight of only 107.8, which is 19.1 smaller than that of iodine 126.9, and the iodized salt is taken by people all year round without obvious toxicity.
Cisplatin, an anticancer drug complexed with heavy metal platinum (atomic weight 195, 1.8 times that of silver), was formally approved for clinical use in the united states in 1978, and became prominent immediately in the treatment of various malignant tumors, while silver ion was a silver ion drug complexed with metallic silver, which was a metal ion type drug as compared with metallic platinum, which was the first only life compared with human life,
unlike common organic medicine, silver ion does not participate in biochemical reaction and metabolism in human body to change its structure, and it can be moved into immune cell with hidden HIV by physiological saline in blood to kill HIV.
Silver is one of trace elements in human tissues, and the harmful heavy metals are lead, arsenic, mercury, cadmium and chromium, and do not contain iron and silver; silver ions (non-silver simple substance) are harmless to high-grade tissue human body, animals, plants and the like, and only kill low-grade microorganism tissues. WHO prescribes that silver has a safety value of 0.05mg.kg for human body -1 Trace silver is harmless to human body, and the content of silver ions in human bodies is too low for some people frequently infected by bacteria and viruses to be one of the important reasons.
Wen Haire professor 2014 reported on Beijing environmental mutagen society that intravenous injection concentration was 5mg.kg via rat tail -1 The concentration of silver ions in the blood of rats is as high as 12.5mg.kg -1 However, the animal body weight is unchanged, the micronucleus rate of bone marrow red blood cells is not obviously increased, and only transient damage is generated to chromosomes of the red blood cells. This also coincides with the experimental test results of the professor Sun Jianfei, the pharmaceutical society of Shandong, et al.
In 2021, 6 months we entrusted with the toxicity experiments of intravenous injection of electrolytic silver ion solution into ear of white blood cell, and by day 10, animals of experimental group had no weight loss, no disturbance of posture, normal diet and urine and no difference from animals of control group. After the animals are sacrificed, kidney function, liver function and lung, liver and kidney tissues are subjected to pathological section observation, and the results are compared with a control group, and all the results are normal, see patent ZL202010395234.6. This also coincides with the experimental test results of the professor Sun Jianfei, the pharmaceutical society of Shandong, et al.
Although students report that silver ions released from the nano silver surface have antiviral properties in a few decades ago, why clinical application has not been achieved so far; which is because of the limitations of the current historical conditions, electrolytic silver ion solutions have not yet emerged.
It should be emphasized that: the electrolytic silver ion solution has high valence, different valence of silver ions, different preparation methods and quite different physical and chemical properties of silver ions, and only the electrolytic silver ion solution which can safely enter blood is the gram of HIV | and the valence of silver ions can be conveniently identified by using 1% sodium hydroxide solution.
The electrolytic silver ion solution is positive and bivalent high valence silver ions, and is characterized in that the electrolytic silver ion solution is obtained by an electrolytic method in an electrolytic tank by utilizing a polar electric field, and has no nitrate component, which is incomparable with products such as a common nitrate system, a nano silver system, a hydrogen peroxide silver ion system and the like in the market.
Oral toxicity of the electrolytic silver ion solution (also high valence electrolytic silver ion solution) of the present invention was detected by a third party: the half lethal dose LD50 of mice oral toxicity is more than 5000mg, which is practically nontoxic (see figure 5).
The injection toxicity of the electrolytic silver ion solution is detected by a third party: 1. the median lethal dose was ld50= 374.11ppm, calculated as the concentration administered; 2. the half-lethal weight of the compound is calculated according to the weight of experimental animals: ld50=3.74 mg/kg body weight, (see fig. 6).
The detection result shows that the injection toxicity of the electrolytic silver ion solution is slight, and when the conventional delivery depth of 50ppm is used for intraperitoneal injection of mice, the mice cannot die by using the maximum dosage, which is consistent with the animal experiment result and the detection result of a third party.
The oxidation-reduction potential of silver ions in the electrolytic silver ion solution is 1.987v, which is much higher than that of monovalent silver ions by 0.798v, and the oxidation-reduction potential of divalent silver ions is 300 times or more of monovalent, so that the electrolytic silver ion solution is also called active silver ions.
The invention adopts a novel preparation method, so the product cost is obviously reduced, the invention is convenient for large-area popularization and use, and is especially suitable for the national conditions of China.
Claims (7)
1. An electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus, which is characterized in that: the electrolytic silver ion solution takes ultrapure water as a solvent, and contains positive divalent silver ions, a complexing agent and a complexing agent; the complexing agent is hexamethylenetetramine which can form a stable complex with silver ions and can quantitatively analyze the concentration of the silver ions; the hexamethylenetetramine is of an analytically pure grade; the complexing agent is analytically pure grade ethylenediamine which can form more stable silver ammino ion, namely diammine silver, with silver ion, and can increase the concentration of the generated silver ammino ion by times; the concentration of the positive divalent silver ions is 200-300 mg kg -1 The method comprises the steps of carrying out a first treatment on the surface of the The maximum concentration of the complexing agent is 0.9g.kg -1 The method comprises the steps of carrying out a first treatment on the surface of the The highest concentration of the complexing agent is 0.55g.kg -1 The method comprises the steps of carrying out a first treatment on the surface of the The p H value of the electrolytic silver ion solution is 10.2-10.5.
2. An electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus, which is characterized in that: the ultrapure water is water with resistivity of 10-12MΩ cm (25 ℃).
3. A preparation method of electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus comprises the following specific steps: the method is characterized in that:
1) Injecting ultrapure water into the electrolytic tank, wherein the horizontal plane is 10cm away from the upper end surface of the electrolytic tank; the electrolytic tank is an insulator, silver electrode plates made of high-purity silver plates are respectively placed at two ends of the electrolytic tank, the specifications of the two silver electrode plates are identical, a stirrer is arranged at the center of the electrolytic tank, the silver electrode plates at the two ends of the electrolytic tank are respectively connected with a direct current power supply capable of automatically reversing the positive electrode and the negative electrode, the positive electrode and the negative electrode are not separated, the positive electrode and the negative electrode can be both positive electrode and negative electrode, the periodic transformation is carried out, and the reversing time is controlled between 1 minutes and 15 minutes;
(2) Starting the stirrer, slowly increasing the rotation speed to 800-1500 rpm, and keeping the water temperature at 15-20 ℃ all the time in the subsequent reaction process based on the highest rotation speed when the water surface is stable and does not overflow 0 C；
(3) Adding a complexing agent and a complexing agent into the electrolytic tank, and stirring to fully dissolve the complexing agent and the complexing agent;
(4) After the complexing agent and the complexing agent are fully dissolved, a direct current power supply capable of automatically reversing the positive electrode and the negative electrode is started, so that the positive electrode or the negative electrode of the silver electrode plate at the two ends is automatically converted within a set time, silver atoms on the high-purity silver plate are electrolyzed to obtain monovalent silver ions, the monovalent silver ions obtained by electrolysis enter water under the attraction of an electric field and then are subjected to complexation reaction with the complexing agent and the complexing agent to generate a diammine silver complex taking positive and divalent silver ions as a core, the two electrode plates are positive-negative electrodes and negative-positive electrodes, the time for automatically reversing the positive electrode and the negative electrode is 1-15 minutes, and the positive electrode and the negative electrode are periodically converted, so that the additional loss of noble metal silver materials is avoided except for silver ions generated in water; in the reaction process, detecting the concentration of positive divalent silver ions in the aqueous solution every 1h, when the concentration of the silver ions is 200-300 mg.kg -1 When the method is used, the automatic positive and negative electrode reverse direct current power supply is turned off timely according to the requirement, the stirrer is only kept to perform aging treatment at the rotating speed of below 200 revolutions, and after the aging treatment time is 48 hours, the PH value of the electrolytic silver ion solution is adjusted to be 10.2-10.5, so that the electrolytic silver ion solution capable of completely inactivating the HIV is obtained.
4. A method for preparing an electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus according to claim 3, wherein: the specification of the direct current power supply capable of automatically reversing the positive electrode and the negative electrode is as follows: the voltage is 10-100V, the current is 0.5-30A, and the time for automatically reversing the positive and negative electrodes is 1-15 minutes.
5. A method for preparing an electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus according to claim 3, wherein: the preparation material of the electrolytic cell is engineering plastic, and the shape of the electrolytic cell is optimal by taking a cube as a best.
6. A method for preparing an electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus according to claim 3, wherein: the purity of the high-purity silver plate in the electrode plate is 99.9-99.99%, the thickness is 0.5-4.0 mm, and the area of the electrode plate is 60-80% of the inner surface area of the two ends of the electrolytic cell.
7. A method for preparing an electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus according to claim 3, wherein: the power of the motor of the stirrer is 1-6 kW, the speed is regulated in a variable frequency mode, the rotating speed range is 60-1800 revolutions, and the blades of the stirrer are engineering plastics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310958412.5A CN116999390A (en) | 2023-08-01 | 2023-08-01 | Electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310958412.5A CN116999390A (en) | 2023-08-01 | 2023-08-01 | Electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116999390A true CN116999390A (en) | 2023-11-07 |
Family
ID=88563111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310958412.5A Pending CN116999390A (en) | 2023-08-01 | 2023-08-01 | Electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116999390A (en) |
-
2023
- 2023-08-01 CN CN202310958412.5A patent/CN116999390A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5079010A (en) | Pharmaceutical preparation for the treatment of wounds, damaged tissue and inflammation in animals | |
| CA2627083C (en) | New highly stable aqueous solution, electrode with nanocoating for preparing the solution and method for making this electrode | |
| CN102499944B (en) | Nanometer silver antibiotic and antiviral compound liquid and its preparation method and products | |
| Bhagavathy et al. | Wound healing and angiogenesis of silver nanoparticle from Azadirachta indica in diabetes induced mice | |
| CN104016923A (en) | Phenytoin derivative as well as preparation method and application thereof | |
| KR20150120852A (en) | Inhalation-type pharmaceutical composition for the treatment of gout and preparation method thereof | |
| CN1751577A (en) | Composite sterilizing agent contg. silver and zinc, prepn. method and application thereof | |
| CN113018436B (en) | Antibacterial metal ion-phthalocyanine/polydopamine nanosphere and preparation method thereof | |
| CN116999390A (en) | Electrolytic silver ion solution capable of completely inactivating human immunodeficiency virus and preparation method thereof | |
| CN111529549B (en) | Antibacterial and antiviral high-valence electrolytic silver ion solution and preparation method thereof | |
| CN1124988C (en) | Activated medical water and its preparing process and usage | |
| CN109568335B (en) | Application of porphyra polysaccharide in intervention of caenorhabditis elegans senescence | |
| JP2009142436A (en) | Aqueous solution for dialysis | |
| US20040138174A1 (en) | Use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cervical erosion | |
| CH706750A2 (en) | Method for the intravenous injection of isotonic-physiological electrolysis water to combat systematic viroses and bacteriosis by means of oxidative radicals. | |
| RU92795U1 (en) | DEVICE FOR INFUSION AND TRANSFUSION THERAPY | |
| CN101904835B (en) | Application of curcumin-zinc compound in preparing bacteriostatic analgesics or health care products | |
| RU2349332C2 (en) | Method of immunodeficiency prevention for newborn calves | |
| CN111870737B (en) | Preparation method of titanium alloy-based antibacterial film | |
| RU2499601C1 (en) | Antiviral composition solution and method for preparing it | |
| CN100344297C (en) | Photocatalyst anti-inflammation antibacterial medicinal ointment and its preparation method | |
| JPH03120220A (en) | Preparative drug and preparation thereof | |
| Ivannikova et al. | Biological aspects of the use of a silver-based preparation in poultry farming | |
| RU2429858C1 (en) | Medical solution for outward application and method for producing thereof | |
| RU2420298C2 (en) | Method of producing aqueous copper-silver compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |